BioSante Pharmaceuticals to Present at Rodman & Renshaw 8th Annual Healthcare Conference
November 03 2006 - 8:00AM
Business Wire
BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced that
Stephen M. Simes, the Company�s president and chief executive
officer, will present a corporate and clinical overview of the
Company at the Rodman & Renshaw 8th Annual Healthcare
Conference, taking place at the New York Palace Hotel in New York
City, on November 6-8, 2006. Mr. Simes� presentation is scheduled
for November 7, 2006 at 3:55 p.m. EST. A live audio webcast of
BioSante�s presentation may be accessed at
http://www.biosantepharma.com/investors/events.html with a replay
available at the same link for 90 days. About BioSante
Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone
therapy products to treat both men and women. These hormone therapy
products are gel formulations for transdermal administration that
deliver bioidentical estradiol and testosterone. BioSante's lead
products include Bio-E-Gel� (transdermal estradiol gel) for the
treatment of women with menopausal symptoms, and LibiGel�
(transdermal testosterone gel) for the treatment of female sexual
dysfunction (FSD). A Bio-E-Gel new drug application (NDA) was
submitted to the FDA in the first quarter 2006. The current market
in the U.S. for estrogen and testosterone products is approximately
$2.5 billion. The transdermal gel formulations used in the women's
gel products are licensed by BioSante from Antares Pharma Inc. The
company also is developing its calcium phosphate nanotechnology
(CaP) for novel vaccines, including avian flu and biodefense
vaccines for toxins such as anthrax and ricin, and drug delivery
systems. Additional information is available online at:
www.biosantepharma.com. BioSante Pharmaceuticals, Inc. (Amex: BPA)
today announced that Stephen M. Simes, the Company's president and
chief executive officer, will present a corporate and clinical
overview of the Company at the Rodman & Renshaw 8th Annual
Healthcare Conference, taking place at the New York Palace Hotel in
New York City, on November 6-8, 2006. Mr. Simes' presentation is
scheduled for November 7, 2006 at 3:55 p.m. EST. A live audio
webcast of BioSante's presentation may be accessed at
http://www.biosantepharma.com/investors/events.html with a replay
available at the same link for 90 days. About BioSante
Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone
therapy products to treat both men and women. These hormone therapy
products are gel formulations for transdermal administration that
deliver bioidentical estradiol and testosterone. BioSante's lead
products include Bio-E-Gel(R) (transdermal estradiol gel) for the
treatment of women with menopausal symptoms, and LibiGel(R)
(transdermal testosterone gel) for the treatment of female sexual
dysfunction (FSD). A Bio-E-Gel new drug application (NDA) was
submitted to the FDA in the first quarter 2006. The current market
in the U.S. for estrogen and testosterone products is approximately
$2.5 billion. The transdermal gel formulations used in the women's
gel products are licensed by BioSante from Antares Pharma Inc. The
company also is developing its calcium phosphate nanotechnology
(CaP) for novel vaccines, including avian flu and biodefense
vaccines for toxins such as anthrax and ricin, and drug delivery
systems. Additional information is available online at:
www.biosantepharma.com.
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jul 2023 to Jul 2024